Glioma detection kit Glican®

for researchMETfor BRAF mutations

Glioma is a tumor that originates from brain neuroglial cells and is the most common primary intracranial tumor. Among them, glioblastoma is the most invasive tumor in the central nervous system (CNS), accounting for the majority (58.4%) of gliomas, with a median overall survival as low as 12-15 months. In the 2021 fifth edition of the World Health Organization (WHO) classification of central nervous system tumors, gliomas are divided into five groups based on histological and molecular pathological characteristics: adult-type diffuse glioma, pediatric-type diffuse low-grade glioma, pediatric-type diffuse high-grade glioma, localized astrocytic tumors, and ependymal tumors. With the advancement of pathology and improvement in pathological testing techniques, particularly the development of next-generation sequencing and epigenetic profiling, the genetic background and mechanisms of glioma occurrence and development are gradually becoming clear. An increasing number of molecular biomarkers have been shown to play important roles in the classification, subtyping, grading, prognosis, and treatment of glioma. DETECTION SIGNIFICANCE 1. Assisting in subtyping: The diagnosis of glioma requires obtaining tumor specimens through surgical resection or biopsy for histological and molecular pathological examinations to determine the pathological grade and molecular subtype. Currently, major molecular pathological markers include IDH1/2, 1p/19q co-deletion, TERT, H3F3A, BRAF , and others. 2. Prognostic assessment: Different molecular subtypes and markers can have different prognostic characteristics.